Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer. Read more on TNGX ...

Tango Therapeutics disclosed a 14% reduction in headcount even as the company shared more evidence that its PRMT5 inhibitor ...

Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic ...

Tango Therapeutics Inc. TNGX on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing ...

Tango Therapeutics has delivered very strong gains in recent years, and that kind of run naturally raises a simple question ...

The new data bolster the theory that patients with pancreatic cancer can derive more benefit from combinations of targeted ...

Tango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating ...

A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in ...

An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.